Is CoQ10 Good for Kidneys? What the Research Shows

CoQ10 shows genuine kidney-protective properties in laboratory and animal research, and a handful of human trials suggest benefits for specific markers like oxidative stress, inflammation, and certain metabolic measures in people with kidney disease. But the evidence that it actually slows kidney function decline in most patients remains thin. The picture is more encouraging in some narrow situations, particularly genetic CoQ10 deficiency and possibly contrast dye-related kidney injury, while being frustratingly inconclusive for the broader question of whether supplementation preserves kidney function in ordinary chronic kidney disease.

Why Kidneys Are Vulnerable to CoQ10 Depletion

Your kidneys are second only to your heart in energy demand. They filter roughly 180 liters of blood per day, and the cells lining the kidney’s tubules are packed with mitochondria to power that work. CoQ10 sits inside those mitochondria, shuttling electrons along the chain that produces cellular energy. It also doubles as an antioxidant, neutralizing the reactive oxygen species that mitochondria inevitably generate as a byproduct.

People with chronic kidney disease tend to have lower circulating CoQ10 levels than healthy individuals, whether they are on dialysis or not.¹ That depletion likely reflects a combination of poor dietary intake, impaired synthesis, and the metabolic stress of kidney disease itself. Lab studies show that when CoQ10 is added back to kidney cells under stress, it reduces the production of damaging reactive oxygen species and restores normal mitochondrial energy production.² This basic mechanism — shoring up mitochondrial function and tamping down oxidative damage — is the rationale behind virtually every kidney-related CoQ10 study.

Metabolic Markers Improve, but Kidney Function Stays Flat

A systematic review and meta-analysis of randomized controlled trials in CKD patients found that CoQ10 supplementation significantly lowered total cholesterol, LDL cholesterol, malondialdehyde (a marker of oxidative damage), and serum creatinine levels.³ On paper, that sounds promising. Creatinine is a waste product that rises as kidney function worsens, and lipid abnormalities drive cardiovascular risk in CKD patients. But before reading too much into those findings, the heterogeneity across studies was high, meaning the individual trial results varied widely.

More importantly, a randomized crossover clinical trial that directly measured kidney function markers found no meaningful change. After CoQ10 treatment, there was no improvement in estimated glomerular filtration rate (the standard measure of how well the kidneys filter), no change in the albumin-to-creatinine ratio (a measure of protein leaking into urine), no change in serum creatinine, and no change in cystatin C, another kidney function marker. Inflammatory markers like C-reactive protein were also unchanged.⁴ This trial is one of the better-designed human studies in the field, and its results are sobering: the metabolic improvements seen in pooled analyses don’t appear to translate into measurable kidney function gains, at least not within the timeframes studied.

This is the central tension in the research. CoQ10 consistently improves surrogate markers — oxidative stress, lipids, some inflammatory signals — while the hard outcomes that patients and nephrologists care about, like filtration rate and protein leakage, remain stubbornly unchanged. Whether longer supplementation or higher doses might bridge that gap is unknown; most trials have lasted only weeks to a few months.

Contrast Dye Injury After Procedures

One area where human data looks more compelling involves contrast-induced kidney injury. When you receive iodine-based contrast dye during a heart catheterization or CT scan, the dye can damage kidney tubular cells through oxidative stress and reduced blood flow. People with diabetes or existing kidney disease are at highest risk.

A single-center trial of 300 patients with acute coronary syndromes found that those given oral CoQ10 before their procedures had a significantly lower rate of contrast-induced kidney injury: roughly 9% in the CoQ10 group versus 21% in the control group. Post-procedure creatinine levels were lower and filtration rates were higher in the CoQ10 group on days two and three.⁵ Animal studies in diabetic rats support this, showing CoQ10 administration before contrast exposure improved kidney function, prevented blood pressure changes, and reduced tissue damage.⁶

This is still a single trial, so it would be premature to call it settled science. But the mechanism fits neatly — contrast dye causes an acute burst of oxidative stress, and CoQ10 is an antioxidant that concentrates in the mitochondria where much of that damage occurs. If these results hold up in larger trials, CoQ10 could become a practical add-on before cardiac procedures in high-risk patients.

Protection Against Drug-Induced Kidney Damage

Much of the strongest evidence for CoQ10’s kidney-protective effects comes from animal models of acute kidney injury caused by toxic drugs. A review of the molecular mechanisms found that CoQ10 treatment showed potent protective effects against kidney injury induced by cisplatin (a common chemotherapy drug), gentamicin (an antibiotic), nonsteroidal anti-inflammatory drugs, shock-wave lithotripsy for kidney stones, sepsis, and ischemia-reperfusion injury — the damage that occurs when blood flow to the kidney is temporarily interrupted and then restored.⁷

Cisplatin nephrotoxicity has been studied in particular detail. In mice given a nephrotoxic dose of cisplatin, CoQ10 treatment significantly reduced blood urea nitrogen and serum creatinine, restored antioxidant defenses, suppressed inflammatory markers like tumor necrosis factor-alpha, and reduced the visible tissue damage seen under a microscope.⁸ Similarly, in models of the herbicide diquat poisoning, CoQ10 protected against acute kidney injury by restoring mitochondrial function.⁹

The limitation is obvious: these are animal and cell studies. Mice receiving intraperitoneal CoQ10 injections are not the same as a cancer patient swallowing a supplement capsule. The doses relative to body weight are often much higher than what humans typically take, and the timing is carefully controlled in ways that real-world use rarely permits. Still, the consistency of the protective effect across multiple different kidney insults is hard to ignore and suggests a genuine biological mechanism, not a statistical fluke.

Dialysis Patients and Inflammation

People on hemodialysis are in a state of chronic oxidative stress and systemic inflammation, which accelerates cardiovascular disease — the leading cause of death in this population. CoQ10 supplementation has been tested in several small dialysis trials, with mixed but somewhat encouraging results on inflammatory markers.

A randomized trial in hemodialysis patients found that CoQ10 significantly lowered C-reactive protein, a key inflammatory marker, and raised albumin levels (low albumin in dialysis patients signals inflammation and poor nutrition). The effect on homocysteine, another cardiovascular risk factor, was not significant.¹⁰ A dose-escalation study found that as CoQ10 doses increased, plasma concentrations of isofurans — a specific marker of oxidative damage — dropped significantly, although another oxidative stress marker (F2-isoprostanes) did not change.¹¹

One Japanese study added a wrinkle: while CoQ10 administration did suppress certain markers of oxidative damage in hemodialysis patients, it simultaneously reduced markers of antioxidant capacity. The researchers interpreted this as the body needing less antioxidant defense because the oxidative stress itself had declined, but the finding is a reminder that “antioxidant” supplements don’t simply push one dial in one direction.¹²

In pediatric hemodialysis patients, a randomized controlled trial found that CoQ10 at roughly 4 mg per kilogram of body weight per day led to significant reductions in blood urea nitrogen, malondialdehyde (a marker of lipid damage from oxidative stress), and tumor necrosis factor-alpha (an inflammatory signal) compared to placebo.¹³ Children on dialysis face especially aggressive inflammation, so even partial improvements in these markers could be clinically meaningful — though again, whether lower inflammatory markers actually translate into fewer complications or better survival hasn’t been tested in this group.

Where CoQ10 Clearly Works: Genetic Deficiency

The one setting where CoQ10 supplementation has produced unequivocal kidney benefits is in patients with primary CoQ10 deficiency, a group of rare genetic conditions where the body cannot synthesize adequate amounts of the molecule. These conditions typically present in childhood as steroid-resistant nephrotic syndrome — the kidneys leak massive amounts of protein into the urine, and standard immunosuppressive drugs don’t help.

In these patients, CoQ10 supplementation essentially corrects the underlying biochemical defect. A study of children with mutations in the ADCK4 gene, one of the genes responsible for CoQ10 biosynthesis, found that supplementation significantly reduced proteinuria while preserving filtration rate over a median follow-up of about a year.¹⁴ A larger study of patients with various primary CoQ10 deficiency mutations reported even more striking results: proteinuria dropped by about 88% at 12 months, and five-year kidney failure-free survival was dramatically better among those treated with CoQ10 — roughly 62% versus 19% in untreated patients.¹⁵ Side effects were uncommon and mild.

The researchers who study these conditions are emphatic: all patients diagnosed with primary CoQ10 deficiency should receive early and lifelong CoQ10 supplementation to slow kidney disease progression.¹⁶ In one case report, urinary CoQ10 levels could even be used to track whether treatment was working, declining in parallel with proteinuria as the patient improved.¹⁷ These genetic conditions are rare, affecting perhaps a few hundred patients worldwide, but they provide proof that when CoQ10 is truly deficient in kidney tissue, restoring it makes a real clinical difference.

Diabetic Kidney Disease

Diabetes is the single most common cause of kidney failure globally, so any supplement that could protect the diabetic kidney would have enormous impact. The evidence for CoQ10 here sits somewhere between the genetic-deficiency success story and the general CKD disappointment.

A meta-analysis of studies in diabetic kidney disease found that CoQ10 supplementation lowered malondialdehyde levels, indicating reduced oxidative damage, compared to control groups receiving standard care or placebo.¹⁸ Animal work is more dramatic: in a genetic mouse model of type 2 diabetes, CoQ10 treatment prevented mitochondrial fragmentation, corrected the glomerular hyperfiltration (an early sign of diabetic kidney damage), and reduced proteinuria — the leaking of protein into the urine that signals progressive disease.¹⁹

The gap between animal findings and human data remains wide, however. No large randomized trial has shown that CoQ10 slows the progression of diabetic kidney disease as measured by hard endpoints like filtration rate decline or time to dialysis. What exists so far is enough to justify further study but not enough to recommend CoQ10 as a diabetic nephropathy treatment.

Blood Pressure, the Silent Kidney Killer

High blood pressure is both a cause and a consequence of kidney disease, so anything that lowers blood pressure could theoretically help preserve kidney function. CoQ10 has a modest reputation as a blood pressure supplement in general cardiology circles, but the kidney-specific data is discouraging. A randomized controlled trial in CKD patients found that omega-3 fatty acids significantly reduced 24-hour ambulatory blood pressure and heart rate, but CoQ10 had no independent effect on blood pressure. In fact, CoQ10 slightly increased heart rate.²⁰ If you’re taking CoQ10 for your kidneys and hoping it will also help your blood pressure, the evidence doesn’t support that expectation in the CKD population specifically.

Ischemia-Reperfusion and Transplant Relevance

When a kidney is transplanted, it undergoes a period without blood flow followed by sudden restoration — ischemia-reperfusion injury. This is the same type of damage that occurs during major surgery or shock, and it contributes to delayed graft function, one of the early complications of transplantation. In a rat model of kidney ischemia-reperfusion, CoQ10 pretreatment reduced tissue oxidative stress, lowered histological damage and cell death scores, and improved functional measures of the ischemic kidney compared to untreated controls.²¹

Separately, in a rat model of heart-attack-induced organ damage, CoQ10 pretreatment protected both the liver and kidneys from the biochemical and structural changes that followed cardiac injury, boosting antioxidant enzyme levels and reducing creatinine concentrations.²² This matters because kidney damage triggered by heart failure — the cardiorenal syndrome — is common in clinical practice and difficult to treat. But both of these lines of evidence remain in animal models. No human transplant or cardiorenal trial of CoQ10 has been completed to date.

Practical Considerations for People With Kidney Disease

If you have kidney disease and are considering CoQ10, a few practical realities are worth knowing. First, most of the human trials used doses in the range of 100 to 600 mg per day for adults, while the pediatric dialysis trial used about 4 mg per kilogram of body weight. CoQ10 is fat-soluble, meaning it absorbs better when taken with a meal that contains some fat. The reduced form (ubiquinol) is generally considered more bioavailable than the oxidized form (ubiquinone), though both have been used in kidney studies.

Safety in kidney disease populations appears reasonable based on the trials conducted so far. The dose-escalation study in hemodialysis patients found the supplement to be well tolerated even at higher doses.¹¹ The pediatric study similarly reported no concerning adverse effects.¹³ CoQ10 can interact with blood thinners like warfarin and may theoretically interact with blood pressure medications, so disclosing supplementation to your nephrologist is not optional — it’s necessary for safe management.

One underappreciated issue is that statins, which are widely prescribed in CKD patients for cardiovascular risk reduction, reduce the body’s endogenous CoQ10 production. Both CoQ10 and cholesterol share a common biosynthetic pathway, so when a statin blocks cholesterol synthesis, CoQ10 production falls as collateral damage. Whether this statin-induced CoQ10 depletion specifically harms the kidneys is debated, but it adds a plausible rationale for co-supplementation in patients who are on statins and already have compromised kidney function.

Why the Field Needs Bigger Trials

The frustrating reality across nearly all the human kidney research on CoQ10 is sample size. Most trials have enrolled somewhere between 30 and 100 patients, last a few weeks to a few months, and measure surrogate markers rather than clinical outcomes. A systematic review protocol published in 2024 acknowledged that while CoQ10 can improve mitochondrial function and decrease oxidative stress in CKD patients, the quality and quantity of evidence remain insufficient to draw firm conclusions about kidney protection.²³ The research community is essentially still at the stage of trying to compile what exists rather than generating definitive new answers.

The contrast-induced nephropathy trial with 300 patients is the largest kidney-focused CoQ10 study to date, and even that was conducted at a single center.⁵ For context, trials that changed clinical practice in nephrology — like the landmark studies of blood pressure targets or SGLT2 inhibitors in kidney disease — enrolled thousands of patients and followed them for years. CoQ10 research is nowhere near that scale. Whether that changes depends partly on funding (supplements are not patentable in the way drugs are, so pharmaceutical investment is limited) and partly on whether smaller mechanistic studies continue to build a case compelling enough to justify the cost of a large outcomes trial.

1
BMJ Open. Efficacy of coenzyme Q10 in patients with chronic kidney disease: protocol for a systematic review
2
FASEB Journal. Coenzyme Q10 alleviates tacrolimus-induced mitochondrial dysfunction in kidney
3
PubMed. The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
4
The Journal of Clinical Investigation. Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease
5
International Journal of Cardiovascular Academy. Coenzyme Q10 in Contrast-induced Nephropathy – A Step Forward in Renal Protection?
6
PubMed Central. Protection of coenzyme Q10 against contrast-induced acute kidney injury in male diabetic rats
7
PubMed Central. Molecular mechanisms underlying the renal protective effects of coenzyme Q10 in acute kidney injury
8
PubMed. Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice
9
PubMed. Protective effect and mechanism of CoQ10 in mitochondrial dysfunction in diquat-induced renal proximal tubular injury
10
PubMed Central. Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients; a randomized clinical trial
11
PubMed Central. Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
12
Blood Purification. Coenzyme Q10 Administration Suppresses both Oxidative and Antioxidative Markers in Hemodialysis Patients
13
Future Journal of Pharmaceutical Sciences. Evaluation of efficacy and safety of coenzyme Q10 in pediatric hemodialysis patients: a randomized controlled trial
14
PubMed. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment
15
PubMed. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency
16
PubMed Central. Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome
17
PubMed Central. Urinary coenzyme Q10 as a diagnostic biomarker and predictor of remission in a patient with ADCK4-associated Glomerulopathy: a case report
18
PubMed Central. Effects of coenzyme Q10 intervention on diabetic kidney disease: A systematic review and meta-analysis
19
PubMed. Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes
20
Journal of Hypertension. The effects of ω3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial
21
Nuclear Medicine Communications. Scintigraphic evaluation of renoprotective effects of coenzyme Q10 in a rat renal ischemia-reperfusion injury
22
PubMed Central. Therapeutic effect of coenzyme-Q10 pretreatment on isoprenaline-induced cardiogenic hepatorenal complications in rats
23
BMJ Open. Renoprotective effects of coenzyme Q10 supplementation in patients with chronic kidney disease: a protocol for a systematic review